OR WAIT null SECS
April 06, 2018
Boehringer Ingelheim and OSE Immunotherapeutics have entered a global immuno-oncology partnership to develop a checkpoint inhibitor for treating advanced solid tumors.
April 05, 2018
The companies have created Syna Therapeutics, a joint venture that will develop biosimilars and new molecules.
The European approval marks the first approval for a biosimilar in that region resulting from the companies’ joint portfolio.
April 03, 2018
The agency has accepted AstraZeneca’s biologics license application for an investigational leukemia drug candidate and granted it priority review.
Pfizer transfers CAR-T assets to Allogene Therapeutics under a new alliance to further develop immuno-oncology therapeutics.
March 29, 2018
The acquisition strengthens Celgene’s position in the global cellular immunotherapy space.
The companies will co-develop and co-promote a CAR T cell therapy in the United States.
Novartis’ Sandoz is seeking approval of its biosimilar referencing Johnson & Johnson’s Remicade (infliximab) for all of Remicade’s indications across gastroenterology, rheumatology, and dermatology.
EMA has recommended approval of the biosimilar for the same indications as Roche’s Herceptin (trastuzumab).
March 28, 2018
Takeda is considering approaching Shire with a possible offer.